spacer
home > ebr > spring 2002 > therapeutic vaccines for hiv-1 infection - past, present and future
PUBLICATIONS
European Biopharmaceutical Review

Therapeutic Vaccines for HIV-1 Infection - Past, Present and Future

The introduction of triple drug combination therapy (highly active antiretroviral therapy, or 'HAART') has had a significant impact on the morbidity and mortality of HIV-1 infection. However, initial optimism regarding the potency of antiretroviral agents was subsequently dampened when it became clear that there were still major obstacles to overcome. Undesirable side effects frequently occur and drug-resistant viruses may emerge if adherence to strict regimes is not maintained. Patients are committed to staying on therapy for life, yet it is unlikely that HIV-1 eradication can be achieved by HAART because of a persistent cellular reservoir of virus. Perhaps the most significant limitation of HAART is its cost: 90 per cent of the 40 million individuals living with HIV-1 infection today live in developing countries and have no access to treatment.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Lucy Dorrell, Clinician Scientist Fellow at the Medical Research Council's Human Immunology Unit

Lucy Dorrell is a Clinician Scientist Fellow at the Medical Research Council Human Immunology Unit, Warrell Institute of Molecular Medicine in Oxford, UK. She is a Principal Investigator in clinical trials of novel therapeutic vaccines for HIV.
Lucy joined the Unit in 1997 and undertook research into cellular immune responses to HIV, based at MRC Laboratories, The Gambia. Prior to this she spent four years at Imperial College School of Medicine, where she took her doctorate degree, and was involved in clinical trials of antiretroviral therapies.

spacer
Dr Lucy Dorrell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers
 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement